LLY

1,152.63

+2%↑

JNJ

231.57

-0.46%↓

ABBV

222.7

-2.04%↓

UNH

405.79

+1.37%↑

MRK

118.84

-1.73%↓

LLY

1,152.63

+2%↑

JNJ

231.57

-0.46%↓

ABBV

222.7

-2.04%↓

UNH

405.79

+1.37%↑

MRK

118.84

-1.73%↓

LLY

1,152.63

+2%↑

JNJ

231.57

-0.46%↓

ABBV

222.7

-2.04%↓

UNH

405.79

+1.37%↑

MRK

118.84

-1.73%↓

LLY

1,152.63

+2%↑

JNJ

231.57

-0.46%↓

ABBV

222.7

-2.04%↓

UNH

405.79

+1.37%↑

MRK

118.84

-1.73%↓

LLY

1,152.63

+2%↑

JNJ

231.57

-0.46%↓

ABBV

222.7

-2.04%↓

UNH

405.79

+1.37%↑

MRK

118.84

-1.73%↓

Inicio・Lista de Acciones・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Abierto

SectorSanidad

1.83 -2.14

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.75

Máximo

1.9

Métricas clave
By Trading Economics
Ingresos	-3.8M -43M
BPA	-0.18
Empleados	150
EBITDA	-3.9M -43M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+363.3% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-45M 742M
Apertura anterior	3.97
Cierre anterior	1.83

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

76 / 344 Clasificación en Healthcare

Allogene Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 jun 2026, 19:20 UTC

Principales Movimientos del Mercado

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

7 jun 2026, 23:46 UTC

Charlas de Mercado

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

7 jun 2026, 23:36 UTC

Charlas de Mercado

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

7 jun 2026, 18:00 UTC

Ganancias

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

6 jun 2026, 12:40 UTC

Adquisiciones, fusiones, absorciones

Correction to Texas Billionaires Article America's Resort -- WSJ

6 jun 2026, 08:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

6 jun 2026, 08:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

6 jun 2026, 04:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 jun 2026, 00:14 UTC

Adquisiciones, fusiones, absorciones

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5 jun 2026, 21:27 UTC

Ganancias

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 jun 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

5 jun 2026, 20:20 UTC

Adquisiciones, fusiones, absorciones

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 jun 2026, 20:19 UTC

Adquisiciones, fusiones, absorciones

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 jun 2026, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

5 jun 2026, 19:26 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 jun 2026, 19:26 UTC

Charlas de Mercado

Hog Futures Tumble to Close Week -- Market Talk

5 jun 2026, 19:10 UTC

Charlas de Mercado

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 jun 2026, 19:03 UTC

Charlas de Mercado

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 jun 2026, 18:59 UTC

Charlas de Mercado

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 jun 2026, 18:47 UTC

Charlas de Mercado

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 jun 2026, 18:34 UTC

Charlas de Mercado

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 jun 2026, 18:33 UTC

Adquisiciones, fusiones, absorciones

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 jun 2026, 17:50 UTC

Ganancias

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 jun 2026, 17:27 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 jun 2026, 16:48 UTC

Adquisiciones, fusiones, absorciones

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

5 jun 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

5 jun 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Allogene Therapeutics Inc previsión

Precio Objetivo

By TipRanks

363.3% repunte

Estimación a 12 Meses

Media 8.71 USD 363.3%

Máximo 14 USD

Mínimo 3.85 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Allogene Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Allogene Therapeutics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

76 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.